PAPERS


14. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium


24. ALLHAT: What has it taught us so far? Leenen FHH. Canadian Medical Assoc J 2004; 171:719-720. (ALLHAT Related Commentary)


33. **Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment.** Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, for the ALLHAT Collaborative Research Group. *Arch Intern Med* 2006; 166:2191-2201. (Paper 28)


42. **Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC, Ford CE, Einhorn PT, Wright JT, Preston RA, Davis BR, Basile JN, Whelton PK, Weiss RJ, Bastien A,


68. **Capsule commentary on Piller et al., Characteristics and long-term follow-up of participants with peripheral vascular disease during ALLHAT.** Williams SK. *J Gen Intern Med.* 2014; 29: 1527-014-2983-x.


70. **Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.** Reisin E, Graves JW, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, Dart


Ancillary Studies


9. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of


15. Gene panels to help identify subgroups at high and low risk of CHD among those randomized to antihypertensive treatment: The GenHAT Study. Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Eric Boerwinkle E, Leieneder-Foster C, Arnett DK.

Pharmacogenetics and Genomics 2012; vol:pp (In Press). (PMCID: PMC3325375)


BOOK CHAPTERS


LETTERS


2. Long-term cardiovascular consequences of diuretics vs. calcium channel blockers vs. angiotensin-converting enzyme inhibitors. Letters to the Editor. Wright JT Jr, Davis BR, Cutler JA, for the ALLHAT Collaborative Research Group. JAMA 2003; 289: 2066-2070. (PMCID:PMCxxxxx)


**ALLHAT RELATED PAPERS**


**ABSTRACTS & PRESENTATIONS**

1. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial: Design features. Davis BR, for the ALLHAT Research Group. Abstract: *Controlled Clinical Trials* 1995; 16(3S):47S. (Presented at 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)

2. Recruitment success by type of site in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Vanguard. Egan D, Pressel SL, Davis BR, on behalf of the ALLHAT Research Group. Abstract: *Controlled Clinical Trials* 1995; 16(Suppl 3):106S. (Presented at the 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.) (Paper 1)


5. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Design and initial characteristics. Cushman WC, for the ALLHAT Research Group. Abstract: *Hypertension* 1995; 25:1356. (Presented at the 11th Scientific meeting of the Inter-American Society of Hypertension; Montréal, Quebec; June 17-20, 1995.) (Paper 3)
6. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and early baseline results.** Grimm RH, Jr, for the ALLHAT Research Group. (Presented at the 11th Asian-Pacific Congress of Cardiology; Bali, Indonesia; September 17-22, 1995.) (Paper 3)

7. **Design and aims of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC. (Presented at the Panhellenic Congress on Arterial Hypertension; Greece, March 1, 1996.)


13. **Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments.** Davis BR, Proschlan M, Ford CE, for the ALLHAT Research Group. (Presented at the International Biometric Conference: Amsterdam, Netherlands; July 1-5, 1996.)

14. **Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments.** Davis BR, Proschlan M, Ford CE, for the ALLHAT Research Group. (Presented at the American Statistical Association Meeting; Chicago, IL; August 4-18, 1996.)

15. **Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on Southeaster Clinical Research.** Cushman WC. (Presented at the 3rd Annual Meeting of the Consortium of Southeaster Hypertension Centers; Research Triangle Park, NC; August 15, 1996.)


17. **Newer vs. older drugs + cholesterol lowering: ALLHAT.** Cutler J. (Presented at the WHO-ISH Collaboration Annual Meeting and Clinical Trials Symposium; St. Jean Cap Ferrat, France; May 1-3, 1997.) (No written material associated with this presentation.)


19. **The impact of external events on on-going clinical trials.** Davis BR, Sacks F, Alderman M, Thornquist M, DeMets DL. Abstract: *Controlled Clinical Trials* 1997; 18(3S):33S. (Presented at the 2nd Joint Meeting of the Society of Clinical Trials/International Society of Clinical Biostatistics; Boston, MA; July 6-10, 1997.)


21. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT.** Oparil S. Abstract: -. (Presented at the 4th International Conference on Preventive Cardiology Satellite Symposium entitled, "Optimal Therapy in the


30. **Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: Preliminary results from ALLHAT.** The ALLHAT Collaborative Research Group. (Presented by C Furberg and BR Davis at the 49th Annual Scientific Session of the American College of Cardiology, Late-Breaking Clinical Trials in Interventional Cardiology (#72), ANAHEIM, CA, March 15, 2000 [10:45 am-12:15 pm].) (Final Paper 1)


ALLHAT results and future directions for hypertension research. Salive ME. (Presented at the American College of Preventive Medicine Meeting, February 22, 2003, San Diego, California.)

AHT Results. Wright J. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.) (Final Paper 2)


Cardiovascular disease (CVD) outcomes in hypertensive patients with impaired renal function. Rahman M, Cutler J, Davis BR, Pressel SL, Whelton P, for the ALLHAT Collaborative Research Group. (Presented by M. Rahman at the National Kidney Foundation 2003 Clinical Meetings, April 2-6, 2003, Dallas, Texas.) (Paper 73)


The ANBP2 and ALLHAT. Cutler J, Barrett S. (Presented at the American Academy of Physician Assistants Meeting, May 26, 2003, New Orleans, Louisiana.) (Paper 63)


ALLHAT. Alderman M. (Presented at the European Society of Hypertension Meeting, June 13-15 [14], 2003, Milan, Italy.)

Results of the ALLHAT trial: Antihypertensive trial results by baseline diabetic & fasting glucose status. Cushman WC, for the ALLHAT Collaborative Research Group. (Presented at the American Diabetes Association Scientific Sessions, June 13-17 [15th], 2003, New Orleans, Louisiana.)

ALLHAT vs. ANBP2. Cushman W. (Presented at the Southern Medical Association 7th Annual Conference on Hypertension, June 27-29 [28], 2003, Myrtle Beach, South Carolina.)

Subgroup analysis of blacks and diabetics. Wright J. (Presented at the National Medical Association Meeting, August 2-7, 2003, Philadelphia, Pennsylvania.)

ALLHAT and JNC 7. Probstfield JL. (Presented at the European Society of Cardiology Meeting, August 30 - September 3, 2003, Vienna, Austria.)
67. **ALLHAT Update.** Furberg C. (Presented at Danish Society of Hypertension Meeting, September 25, 2003, Copenhagen, Denmark.)


69. **Cardiovascular disease and renal disease outcomes in hypertensive patients with various levels of baseline renal function.** Rahman M. (Presented at the 2003 Annual Scientific Assembly of the American Academy of Family Physicians, October 1-5 (4th), 2003, New Orleans, Louisiana.) (Paper 43)

70. **Effects of ACE inhibitor and calcium channel blocker compared with diuretic in high-risk hypertensive person: Further results from ALLHAT.** Hassman J. (Presented at the American Osteopathic Association American College of Osteopathic Family Physicians Meeting, October 14, 2003, New Orleans, Louisiana.)


72. **Results from ALLHAT.** Cushman W. (Presented to the Texas Chapter of the American Society of Hypertension, October 18, 2003, Houston, Texas.)

73. **What have we learned from ALLHAT?** Leenen F. (Presented at Canadian Cardiovascular Congress Meeting, October 2529 (26), 2003, Toronto, Canada.

74. **Hypertension treatment and diabetes.** Davis BR. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29, 2003, Santiago, Chile.)

75. **First step therapy for hypertension ALLHAT.** Davis BR. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29, 2003, Santiago, Chile.)

76. **Heart failure, LVH, hypertension and treatment.** Davis BR. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29, 2003, Santiago, Chile.)

77. **ALLHAT: The key findings.** Furberg C. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)

78. **ALLHAT results for subgroups and secondary outcomes.** Probstfield JL. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)

79. **After NHANES, ALLHAT and JNC-VII: How can we implement the findings?** Whelton PK. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)


82. **Incidence of end stage renal disease (ESRD) and cardiovascular disease (CVD) in high risk hypertensive patients with reduced glomerular filtration rate (GFR).** Rahman M. (Presented at the American Society of Nephrology Meeting, November 16, 2003, San Diego, California.) (Paper 73)

83. **ALLHAT: Main results and clinical implications.** Cutler J. (Presented at the American Society of Health-System Pharmacists Meeting, December 9, 2003, New Orleans, Louisiana.)

84. **ALLHAT: Cost-effectiveness analysis and societal implications.** Heidenreich P. (Presented at the American Society of Health-

86. **New data from ALLHAT.** Alderman M. (Presented at the International Society of Hypertension Meeting, February 15-17, 2004, Sao Paulo, SP, Brazil.)


96. **ALLHAT: Results and implications for older patients.** Williamson J. (Presented at the American Society of Hypertension 2004, New Orleans, Louisiana.)

97. **Heart failure results in ALLHAT.** Davis B. (Presented at the European Society of Cardiology Scientific Sessions, August 28-September 1, 2004 [8/29], Munich, Germany.) (Paper 46)

98. **Preserved and impaired left ventricular systolic function in ALLHAT.** Kostis J. (Presented at the European Society of Cardiology Scientific Sessions, August 28September 1, 2004 [9/1], Munich, Germany.) (Paper 52)

99. **Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and normoglycemia.** Thadani T. (Presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.) (Paper 38)

100. **Heart failure results in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Leenen F. (Poster presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.) (Paper 46)

102. **Clinical outcomes in ALLHAT antihypertensive trial participants with cardiovascular dysmetabolic syndrome.** Davis B. (Presented at 77th Annual Scientific Sessions of the American Heart Association, November 7-10, 2004, New Orleans, Louisiana.) (Paper 48)


104. **Outcomes in high-risk hypertensives randomized to CCB vs. ACE inhibitor in ALLHAT.** Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. (Presented by Frans Leenen at 20 Annual Scientific Meeting of the American Society of Hypertension, May 14-18, 2005, San Francisco, CA.) (Paper 78)

105. **Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive persons: The GenHAT Study.** Davis B. (Presented by Barry Davis at 20 Annual Scientific Meeting of the American Society of Hypertension, May 1418, 2005, San Francisco, CA.) (Paper 68 -GenHAT)


109. **Cardiovascular and renal outcomes in patients with diabetes.** Davis B. (Presented at the Blood Pressure Lowering Treatment Trialists’ Collaboration Symposium, June 16, 2005, Milan, Italy.)

110. **Cardiovascular outcomes in hypertensives with CHD randomized to amlodipine versus lisinopril in ALLHAT.** Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.) (Paper 78)

111. **Outcomes in high-risk hypertensives randomized to CCB vs. ACE inhibitor in ALLHAT.** Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.) (Paper 78)

112. **Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive persons: The GenHAT Study.** Davis B. (European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.) (Paper 68 -GenHAT)

113. **Clinical outcomes in participants with metabolic syndrome in ALLHAT.** Black H, Davis B. (Presented by Henry Black at European Society of Hypertension Scientific Sessions, June 17-21[19], 2005, Milan, Italy.) (Paper 48)

114. **Clinical outcomes by race in non-diabetic participants with cardiovascular dysmetabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Wright JT Jr, Davis BR, Black HR, for ALLHAT Collaborative Research Group. (Oral presentation by Jackson Wright at International Society of Hypertension In Blacks, July 15-19, 2005, San Juan, Puerto Rico.) (Paper 48)


119. Activism to promote health of patients and the public. Katz (Presented by Katz at 29 Annual Meeting of the Society of General Internal Medicine, April 26-29, 2006, Los Angeles, California.) (ALLHAT Dissemination)


123. Metabolic results in hypertension trials. (Presented by Barry Davis, Invited speaker in debate with Mark Houston at 21 Annual Scientific Meeting of the American Society of Hypertension, May 17-20, 2006, New York, New York.)


126. Clinical outcomes by race in participants with the metabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial on doxazosin vs. chlorthalidone. Wright JT, Davis BR, Haywood J, Einhorn P, Pressel SL, for the ALLHAT Collaborative Research Group. (Presented by Jackson Wright at the International Society on Hypertension In Blacks Meeting, June 23-26, 2006, Atlanta, Georgia.) Oral and poster presentation. (Paper 91)

127. (Presented by Terri Geraci at American Academy of Nurse Practitioners, June 20-24, 2006, Grapevine, Texas.)

128. Megatrails: ALLHAT. Davis BR. (Invited presentation by Barry Davis at American Statistical Association Meeting, August 6-10, 2006, Seattle, Washington.)


136. ALLHAT findings revisited 5 years later in the context of subsequent analyses. Probstfield JL, Wright JT, Einhorn PT, Pressel SL, Davis BR, for the ALLHAT Investigators. (Presented by Jeff Probstfield at the European Society of Cardiology Congress 2008, August 30-September 3, 2008, Munich, Germany.) (Paper 92)


145. ALLHAT: Long-term outcomes of drug treatment in high CHD risk hypertensive patients. Overview of ALLHAT post-trial follow-up. Davis, BR. (Presented May 2nd by Barry Davis at the 25th Annual Scientific Meeting and Exposition of the American


